Share
June 2019 News from Champions Oncology

Covering a full range of research and development solutions that help guide decision making for clinical oncology drug development, here's where you can stay up-to-date on news, events, and special opportunities for study enrollment.

MODEL SPOTLIGHT - Osimertinib Insensitive Ex20 EGFR Mut NSCLC PDX


With the lack of approved therapies targeting EGFR Exon 20 mutations - new and relevant pre-clinical models are required to identified novel, effective therapies.

Champions has developed the NSCLC PDX model CTG-2842 which harbors the Ex20 insertion V769_D770 ASV.

In vivo testing of this model with osimertinib resulted in Progressive Disease. Read more about this model in the first of our spotlight series here.

Champions In Vivo AML Screen -
Now Enrolling


Enroll in our inaugural In Vivo screen utilizing systemic PDX models of primary patient AML samples.

10 PDX models are available to run on study, with significant cost savings compared to stand-alone studies.

Limited availability, enrollment closes July 31st, 2019. Click here for further information.

Champions Announces Partnership with Transcure Bioservices for Humanized Mouse Studies


This newly signed partnership combines Champions’ patient sourced cancer models with TransCure’s full human immune system mouse models for more predictive preclinical cancer drug development both throughout Europe and Globally.
Customers are offered access to a centralized and unique set of interactions with the respective companies allowing to perform PDX studies and the pharmacology work, reducing the intercontinental logistics involved with performing the work only in the US. Read more here.

Children's Cancer Therapy Development Institute Utilizes Champions'
RMS Sarcoma PDX

A recent publication by Dr Bharathy at the cc-TDI has investigated whether entinostat  has antitumor activity in fusion-negative eRMS either as a single agent or in combination with vincristine.

The use of Champion's Rhabdomyosarcoma PDX models were instrumental in understanding the activity of these agents in vivo. Read the publication here.
Please contact Armelle Logie today at alogie@championsoncology.com or
+44-7445 989 574 for more information

Copyright © 2019, All rights reserved.

Our mailing address is:
Corporate Headquarters
One University Plaza
Suite 307
Hackensack, NJ 07601

Champions TumorGraft is a registered trademark of Champions Oncology

 
 

Email Marketing by ActiveCampaign